SPARC and obesity disorder: In summary, the activation of EP3 receptor inhibits HFD-induced obesity in mice by promoting macrophage releasing SPARC via the PKA/Sp1/Dnmt1,3a pathway, indicating that the EP3 receptor may be an attractive therapeutic target for obesity.